

# Joseph J Shatzel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2105929/publications.pdf>

Version: 2024-02-01

95  
papers

1,996  
citations

304368

22  
h-index

288905

40  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2407  
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. <i>Platelets</i> , 2022, 33, 66-72.	1.1	18
2	Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. <i>Platelets</i> , 2022, 33, 404-415.	1.1	13
3	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1636-1662.e36.	2.4	95
4	Severe thrombocytopenia in adults undergoing extracorporeal membrane oxygenation is predictive of thrombosis. <i>Platelets</i> , 2022, 33, 570-576.	1.1	10
5	Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. <i>European Journal of Haematology</i> , 2022, 108, 271-277.	1.1	11
6	Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. <i>Current Problems in Cancer</i> , 2022, 46, 100832.	1.0	2
7	Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12692.	1.0	6
8	Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions. <i>JAMA Network Open</i> , 2022, 5, e224488.	2.8	24
9	Travel-Associated Venous Thromboembolism. <i>Wilderness and Environmental Medicine</i> , 2022, 33, 169-178.	0.4	10
10	Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. <i>Cellular and Molecular Bioengineering</i> , 2022, 15, 231-243.	1.0	5
11	Anticoagulation in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 536-545.	1.1	4
12	Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2022, 216, 1-7.	0.8	6
13	Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. <i>Cancer</i> , 2022, 128, 3224-3232.	2.0	12
14	Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 161-175.	1.0	12
15	Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. <i>ASAIO Journal</i> , 2021, 67, 290-296.	0.9	115
16	The hematologic consequences of obesity. <i>European Journal of Haematology</i> , 2021, 106, 306-319.	1.1	70
17	Anticoagulation strategies in extracorporeal circulatory devices in adult populations. <i>European Journal of Haematology</i> , 2021, 106, 19-31.	1.1	28
18	Heparin Resistance Is Common in Patients Undergoing Extracorporeal Membrane Oxygenation but Is Not Associated with Worse Clinical Outcomes. <i>ASAIO Journal</i> , 2021, 67, 899-906.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Thrombin generation and activity in multiple sclerosis. <i>Metabolic Brain Disease</i> , 2021, 36, 407-420.	1.4	9
20	Factor XII plays a pathogenic role in organ failure and death in baboons challenged with <i>Staphylococcus aureus</i> . <i>Blood</i> , 2021, 138, 178-189.	0.6	15
21	CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. <i>European Journal of Haematology</i> , 2021, 106, 634-642.	1.1	28
22	Role of platelets in regulating activated coagulation factor XI activity. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C365-C374.	2.1	12
23	Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C902-C915.	2.1	22
24	The hemostatic and thrombotic complications of liver disease. <i>European Journal of Haematology</i> , 2021, 107, 383-392.	1.1	9
25	Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone. <i>Thrombosis Research</i> , 2021, 207, 96-98.	0.8	12
26	Platelet integrin activation surfs the calcium waves. <i>Platelets</i> , 2021, 32, 437-439.	1.1	2
27	A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis. <i>Blood</i> , 2021, 138, 669-669.	0.6	1
28	Iron Repletion Increases Platelet Aggregation and Reduces Platelet Count in Iron Deficient Premenopausal Women. <i>Blood</i> , 2021, 138, 3170-3170.	0.6	0
29	Prior History of Thrombosis, Meld, BMI and the Presence of Esophageal Varices Predict Thrombus Progression in Patients with Untreated Splanchnic Vein Thrombosis. <i>Blood</i> , 2021, 138, 1058-1058.	0.6	0
30	The role of iron repletion in adult iron deficiency anemia and other diseases. <i>European Journal of Haematology</i> , 2020, 104, 153-161.	1.1	65
31	Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single-center retrospective study. <i>European Journal of Haematology</i> , 2020, 104, 55-58.	1.1	6
32	Transfusion strategies in patients with cirrhosis. <i>European Journal of Haematology</i> , 2020, 104, 15-25.	1.1	29
33	The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. <i>European Journal of Haematology</i> , 2020, 104, 79-87.	1.1	112
34	Thromboelastography Better Reflects Hemostatic Abnormalities in Cirrhotics Compared With the International Normalized Ratio. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 741-746.	1.1	24
35	Going Skin Deep: Excavating a Diagnosis of Intravascular Large B Cell Lymphoma. <i>Journal of General Internal Medicine</i> , 2020, 35, 3368-3371.	1.3	0
36	Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents for Use in COVID-19 Patients. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 331-339.	1.0	6

#	ARTICLE	IF	CITATIONS
37	A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency. <i>American Journal of Hematology</i> , 2020, 95, 1572-1577.	2.0	10
38	When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 602-605.	1.0	2
39	Diagnosis and management of hereditary haemochromatosis. <i>Vox Sanguinis</i> , 2020, 115, 255-262.	0.7	27
40	Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 179-187.	1.0	2
41	The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020, 105, 360-362.	1.1	11
42	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Blood</i> , 2020, 136, 23-24.	0.6	2
43	The Prevalence and Management of Secondary Erythrocytosis in Transgender Individuals Undergoing Masculinizing Therapy. <i>Blood</i> , 2020, 136, 13-13.	0.6	1
44	Practice Patterns in Hospitalized Adult Patients with Hemophilia: A Survey Study of US Hemophilia Centers. <i>Blood</i> , 2020, 136, 26-26.	0.6	0
45	The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 502-508.	1.5	49
46	Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk?. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 807-809.	0.6	12
47	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 799-809.	1.1	68
48	The efficacy and safety of a catheter removal only strategy for the treatment of PICC line thrombosis versus standard of care anticoagulation: a retrospective review. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 585-589.	1.0	11
49	Biopsy-proven thrombotic microangiopathy without schistocytosis on peripheral blood smear: A cautionary tale. <i>American Journal of Hematology</i> , 2019, 94, E234-E237.	2.0	10
50	Modeling the effect of blood vessel bifurcation ratio on occlusive thrombus formation. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2019, 22, 972-980.	0.9	7
51	A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system. <i>European Journal of Haematology</i> , 2019, 103, 43-46.	1.1	5
52	Anticoagulation in the cardiac patient: A concise review. <i>European Journal of Haematology</i> , 2019, 102, 3-19.	1.1	9
53	The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature. <i>European Journal of Haematology</i> , 2019, 102, 312-318.	1.1	53
54	Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?. <i>Platelets</i> , 2019, 30, 796-798.	1.1	11

#	ARTICLE	IF	CITATIONS
55	The role of coagulation and platelets in colon cancer-associated thrombosis. American Journal of Physiology - Cell Physiology, 2019, 316, C264-C273.	2.1	48
56	Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism. JAMA Oncology, 2019, 5, 141.	3.4	13
57	Venous thrombosis in unusual sites: A practical review for the hematologist. European Journal of Haematology, 2019, 102, 53-62.	1.1	25
58	Bleeding and Thrombotic Outcomes in Anticoagulant Free Extracorporeal Membrane Oxygenation (ECMO) in Adults: A Systematic Review. Blood, 2019, 134, 2436-2436.	0.6	5
59	Antithrombotic Therapy for Cardiac Disease. , 2019, , 131-138.		0
60	Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signaling Organization and Platelet Function. Blood, 2019, 134, 2074-2074.	0.6	0
61	The Safety of Novel Drugs Targeting Factor XI and XII in Human Clinical Trials:a Systematic Review. Blood, 2019, 134, 4966-4966.	0.6	1
62	Efficacy and Safety of Low Molecular Weight Iron Dextran (LMWID) Vs. Ferumoxytol in Treating Iron Deficiency Anemia. Blood, 2019, 134, 2449-2449.	0.6	1
63	Predictive and Prognostic Factors Associated with the Incidence and Mortality of Hematologic Malignancies. Blood, 2019, 134, 5893-5893.	0.6	0
64	PFO closure for secondary stroke prevention: is the discussion closed?. Journal of Thrombosis and Thrombolysis, 2018, 46, 74-76.	1.0	2
65	Cryptogenic acute limb ischemia: a retrospective cohort study defining a previously undescribed clinical entity. Journal of Thrombosis and Thrombolysis, 2018, 45, 397-402.	1.0	4
66	Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. Platelets, 2018, 29, 773-778.	1.1	12
67	Evaluating the Effects of an Evidence-Based Hemostasis and Thrombosis Treatment Algorithm on Medical Practitioner and Trainee Clinical Decision-Making. Seminars in Thrombosis and Hemostasis, 2018, 44, 400-403.	1.5	1
68	More efficacious, equally safe: a meta-analysis comparing the safety of direct oral anticoagulants versus aspirin. Journal of Thrombosis and Thrombolysis, 2018, 46, 22-23.	1.0	2
69	The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient Sample. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 74-77.e1.	0.2	20
70	Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units. Cardiovascular Engineering and Technology, 2018, 9, 515-527.	0.7	3
71	Design and Utility of a Point-of-Care Microfluidic Platform to Assess Hematocrit and Blood Coagulation. Cellular and Molecular Bioengineering, 2018, 11, 519-529.	1.0	10
72	The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. Frontiers in Oncology, 2018, 8, 78.	1.3	73

#	ARTICLE	IF	CITATIONS
73	When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. American Journal of Nephrology, 2018, 48, 96-107.	1.4	45
74	Arterial thrombosis in unusual sites: A practical review. European Journal of Haematology, 2018, 101, 728-736.	1.1	14
75	Off-label use of 4-factor prothrombin complex concentrate is common despite little known benefit: A retrospective study. European Journal of Haematology, 2018, 101, 349-353.	1.1	9
76	Reversal of warfarin era thinking. Journal of Internal Medicine, 2018, 283, 408-410.	2.7	5
77	The Epidemiology and Clinical Associations of Portal Vein Thrombosis in Hospitalized Patients With Cirrhosis: A Nationwide Analysis From the National Inpatient Sample. Journal of Hospital Medicine, 2018, 13, 324-325.	0.7	2
78	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. Journal of Thrombosis and Haemostasis, 2017, 15, 835-847.	1.9	191
79	What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. Seminars in Oncology, 2017, 44, 8-12.	0.8	14
80	The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. European Journal of Haematology, 2017, 98, 393-397.	1.1	132
81	Syndromes of Thrombotic Microangiopathy. Medical Clinics of North America, 2017, 101, 395-415.	1.1	61
82	Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis. Blood, 2017, 129, 653-655.	0.6	18
83	Rapid and durable response to intravenous immunoglobulin in delayed heparin-induced thrombocytopenia: a case report. Transfusion, 2017, 57, 919-923.	0.8	15
84	Treatment of individuals who cannot receive blood products for religious or other reasons. American Journal of Hematology, 2017, 92, 1370-1381.	2.0	40
85	Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma. Haemophilia, 2017, 23, e453-e456.	1.0	1
86	Thrombotic issues in transgender medicine: A review. American Journal of Hematology, 2017, 92, 204-208.	2.0	81
87	Mononucleosis-induced pseudo neutropenia. American Journal of Hematology, 2017, 92, 219-219.	2.0	0
88	The Safety of Low-Molecular-Weight Heparin During and After Pregnancy. Obstetrical and Gynecological Survey, 2017, 72, 721-729.	0.2	22
89	The Rise Of Bloodless Medicine: How We Treat Those Who Cannot Receive Blood Products for Religious Or Other Reasons. , 2017, , .		0
90	Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. Thrombosis and Haemostasis, 2016, 116, 397-400.	1.8	18

#	ARTICLE	IF	CITATIONS
91	The "platelet boilermaker": A treatment protocol to rapidly increase platelets in patients with immune-mediated thrombocytopenia. American Journal of Hematology, 2016, 91, E330-1.	2.0	5
92	The Effectiveness and Safety of Direct Oral Anticoagulants (DOACs) Vs. Traditional Anticoagulants in Patients with Cirrhosis. Blood, 2016, 128, 5015-5015.	0.6	2
93	The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A Review of 10,972 Admissions from the 2012 National Inpatient Sample. Blood, 2015, 126, 1314-1314.	0.6	9
94	Characteristics of Upper Extremity Deep Vein Thrombosis in Hospitalized Patients. a Review of 8350 Admissions from the 2012 National Inpatient Sample. Blood, 2015, 126, 2314-2314.	0.6	0
95	The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample. Blood, 2015, 126, 1091-1091.	0.6	0